Hormonal
PPAR gamma 2 prevents lipotoxicity in non-adipose tissues (liver, muscle, pancreas) by facilitating the deposition of fat as harmless triacylglycerols (TAGs) instead of reactive lipid species like ceramides and diacylglycerols (DAGs).
This mechanism highlights the importance of how the body handles excess fat. When the body can safely store fat as triglycerides within cells, it avoids the toxic effects of other lipid byproducts that damage cells and cause insulin resistance. This suggests that supporting healthy lipid storage pathways is crucial for metabolic health.
Lipidomic analyses suggest that PPARg2 plays an important antilipotoxic role when induced ectopically in liver and muscle by facilitating deposition of fat as relatively harmless triacylglycerol species and thus preventing accumulation of reactive lipid species.
Why this rating
Supported by detailed lipidomic analysis (LC/MS) across multiple tissues.
Source
PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism
Gema Medina‐Gómez et al. · PLoS Genetics · 2007
DOI 10.1371/journal.pgen.0030064
More from this paper
- Ablation of the PPAR gamma 2 isoform prevents adipose tissue expansion, leading to lipotoxicity, severe insulin resistance, and beta-cell failure despite reduced total fat mass.Good
- PPAR gamma 2 is required for the adaptive beta-cell hyperplasia and hypertrophy that normally compensates for insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →